

## In the Claims

Please amend the claims as follows:

1. (Currently Amended) A method of inducing a body to produce an antibody against the region of the CCR5 receptor in wild type individuals, that interacts with the region that comprises the delta 32 deletion, said method comprising administering a vaccine including a polypeptide having the following sequence:

Tyr-Ser-Gln-Tyr-Gln-Phe-Trp-Lys-Asn-Phe-Gln-Thr-Leu-  
Lys-Ile-Val-Ile-Leu-Gly-Leu-Val-Leu-Pro-Leu-Leu-Val-  
Met-Val-Ile-Cys-Tyr-Ser-Gly-Ile-Leu-Lys-Thr-Leu-Leu-Arg-  
Cys-Arg-Asn-Glu-Lys-Lys-Arg, (SEQ ID NO:1).

2. (Original) The method according to claim 1 wherein the vaccine is a derivative of said polypeptide.

3. (Previously presented) The method according to claim 1 wherein said vaccine produces an antibody with specificity for the CCR5 receptor.

4. (Currently amended) A method of treating a patient infected with HIV comprising using a vaccine including a polypeptide having the following sequence :

Application No. 09/846,687

Tyr-Ser-Gln-Tyr-Gln-Phe-Trp-Lys-Asn-Phe-Gln-Thr-Leu-  
Lys-Ile-Val-Ile-Leu-Gly-Leu-Val-Leu-Pro-Leu-Leu-Val-  
Met-Val-Ile-Cys-Tyr-Ser-Gly-Ile-Leu-Lys-Thr-Leu-Leu-Arg-  
Cys-Arg-Asn-Glu-Lys-Lys-Arg, (SEQ ID NO:1).

wherein said vaccine produces an antibody against the region of the CCR5 receptor in wild type individuals, that is affected by the delta 32 deletion.

5. (Original) The method according to claim 2 wherein the vaccine is a derivative of said polypeptide.

6. (Withdrawn) A vaccine for producing an antibody against the region of the CCR5 receptor in wild type individuals, that is affected by the delta 32 deletion comprising a polypeptide having the following sequence:

Tyr-Ser-Gln-Tyr-Gln-Phe-Trp-Lys-Asn-Phe-Gln-Thr-Leu-Lys-Ile-Val-Ile-  
Leu-Gly-Leu-Val-Leu-Pro-Leu-Leu-Val-Met-Val-Ile-Cys-Tyr-Ser-Gly-Ile-  
Leu-Lys-Thr-Leu-Leu-Arg-Cys-Arg-Asn-Glu-Lys-Lys-Arg, (SEQ ID  
NO:1).

7. (Previously Presented) A method of vaccination comprising administering a polypeptide to an individual, said polypeptide causing said individual to generate antibodies in response to said polypeptide, said antibodies inhibiting the activity of

Application No. 09/846,687

receptors through binding.

8. (Currently Amended) The method according to claim 7 wherein said polypeptide has the following sequence:

Tyr-Ser-Gln-Tyr-Gln-Phe-Trp-Lys-Asn-Phe-Gln-Thr-Leu-Lys-Ile-Val-Ile-  
Leu-Gly-Leu-Val-Leu-Pro-Leu-Leu-Val-Met-Val-Ile-Cys-Tyr-Ser-Gly-Ile-  
Leu-Lys-Thr-Leu-Leu-Arg-Cys-Arg-Asn-Glu-Lys-Lys-Arg, (SEQ ID  
NO:1).

9. (Original) The method according to claim 8 wherein the vaccine is a derivative of said polypeptide.

10. (Original) The method according to claim 9 wherein said vaccine produces an antibody bound to the CCR5 site.